This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Apr 24:350:h1679.

doi: 10.1136/bmj.h1679.

Safety of new oral anticoagulants

Mary S Vaughan Sarrazin¹, Adam Rose²

Affiliations

Affiliations

¹ Comprehensive Access and Delivery Research and Evaluation Center (CADRE), Iowa City VA Medical Center, Iowa City, IA 52246, USA Department of Internal Medicine, Roy J and Lucille A Carver College of Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA.
² Center for Healthcare Organization and Implementation Research (CHOIR), Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA 01730, USA Medical Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.

PMID: 25911527
DOI: 10.1136/bmj.h1679

Editorial

Safety of new oral anticoagulants

Mary S Vaughan Sarrazin et al. BMJ. 2015.

. 2015 Apr 24:350:h1679.

doi: 10.1136/bmj.h1679.

Authors

Mary S Vaughan Sarrazin¹, Adam Rose²

Affiliations

¹ Comprehensive Access and Delivery Research and Evaluation Center (CADRE), Iowa City VA Medical Center, Iowa City, IA 52246, USA Department of Internal Medicine, Roy J and Lucille A Carver College of Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA.
² Center for Healthcare Organization and Implementation Research (CHOIR), Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA 01730, USA Medical Center and Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.

PMID: 25911527
DOI: 10.1136/bmj.h1679

No abstract available

PubMed Disclaimer

Comment in

Effective antidotes for new anticoagulants.
Lythgoe M. Lythgoe M. BMJ. 2015 May 26;350:h2775. doi: 10.1136/bmj.h2775. BMJ. 2015. PMID: 26014356 No abstract available.

Comment on

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Abraham NS, et al. BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857. BMJ. 2015. PMID: 25910928 Free PMC article.
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Chang HY, et al. BMJ. 2015 Apr 24;350:h1585. doi: 10.1136/bmj.h1585. BMJ. 2015. PMID: 25911526 Free PMC article.

Similar articles

Effective antidotes for new anticoagulants.
Lythgoe M. Lythgoe M. BMJ. 2015 May 26;350:h2775. doi: 10.1136/bmj.h2775. BMJ. 2015. PMID: 26014356 No abstract available.
Anticoagulation therapy: Bleeding no worse with novel agents.
Phillips R. Phillips R. Nat Rev Cardiol. 2015 Jul;12(7):381. doi: 10.1038/nrcardio.2015.75. Epub 2015 May 12. Nat Rev Cardiol. 2015. PMID: 25962977 No abstract available.
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Abraham NS, et al. BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857. BMJ. 2015. PMID: 25910928 Free PMC article.
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Desai J, Kolb JM, Weitz JI, Aisenberg J. Desai J, et al. Thromb Haemost. 2013 Aug;110(2):205-12. doi: 10.1160/TH13-02-0150. Epub 2013 May 23. Thromb Haemost. 2013. PMID: 23702623 Review. No abstract available.
Oral anticoagulants: the move beyond warfarin.
Frei J, Carroll VS. Frei J, et al. J Neurosci Nurs. 2014 Oct;46(5):253-5. doi: 10.1097/JNN.0000000000000085. J Neurosci Nurs. 2014. PMID: 25188682 Review. No abstract available.

See all similar articles

Cited by

The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis.
Liang X, Xie W, Lin Z, Liu M. Liang X, et al. Anatol J Cardiol. 2021 Feb;25(2):77-88. doi: 10.14744/AnatolJCardiol.2020.18049. Anatol J Cardiol. 2021. PMID: 33583814 Free PMC article.
Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions.
Monaco L, Biagi C, Conti V, Melis M, Donati M, Venegoni M, Vaccheri A, Motola D. Monaco L, et al. Br J Clin Pharmacol. 2017 Jul;83(7):1532-1543. doi: 10.1111/bcp.13234. Epub 2017 Mar 19. Br J Clin Pharmacol. 2017. PMID: 28071818 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Medical
- MedlinePlus Health Information